Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 13/20 | 0.39 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.34 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.34 |
| ▸ | LTA4H | P09960 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21597934 | 0.99 | MAPK1 (0.41) | MAPK1CHRM1CHRM5CHRM2MEN1 | |
| SCHEMBL22449317 | 0.89 | MMP13 (0.34) | KMT2AAOC3LTA4H | |
| SCHEMBL22449321 | 0.88 | MMP13 (0.34) | MAPK1KMT2AAOC3LTA4H | |
| SCHEMBL22472890 | 0.85 | MAPK1 (0.41) | MAPK1CHRM1CHRM5CHRM2MEN1 | |
| SCHEMBL22472926 | 0.84 | MAPK1 (0.43) | MAPK1CHRM1CHRM5CHRM2MEN1 | |
| SCHEMBL27176063 | 0.84 | LTA4H (0.35) | AOC3LTA4H | |
| SCHEMBL27176059 | 0.83 | LTA4H (0.34) | AOC3LTA4H | |
| SCHEMBL21597928 | 0.77 | MAPT (0.48) | CHRM1KMT2A | |
| SCHEMBL21597933 | 0.76 | ALDH1A1 (0.50) | MAPK1CHRM1MEN1KMT2A | |
| SCHEMBL22472924 | 0.74 | MMP13 (0.36) | MAPK1KMT2AAOC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112585143-B | Bridging compounds as agonists of muscarinic M1 and/or M4 receptors | 奈克斯拉制药英国有限公司 | 2024-11-12 | — | — | CN | claimed |
| EP-3810614-B1 | BRIDGED COMPOUNDS AS AGONISTS OF THE MUSCARINIC M1 AND/OR M4 RECEPTOR | HEPTARES THERAPEUTICS LTD (GB) | 2024-03-27 | — | — | EP | claimed |
| US-10787447-B2 | Pharmaceutical compounds | HEPTARES THERAPEUTICS LIMITED (GB) | 2020-09-29 | — | — | US | claimed |
| EP-3810614-B1 | BRIDGED COMPOUNDS AS AGONISTS OF THE MUSCARINIC M1 AND/OR M4 RECEPTOR | HEPTARES THERAPEUTICS LTD (GB) | 2024-03-27 | — | — | EP | disclosed |
| US-11773090-B2 | Pharmaceutical compounds | HEPTARES THERAPEUTICS LIMITED (GB) | 2023-10-03 | — | — | US | disclosed |
| US-11773090-B2 | Pharmaceutical compounds | HEPTARES THERAPEUTICS LIMITED (GB) | 2023-10-03 | — | — | US | disclosed |
| US-20210002271-A1 | PHARMACEUTICAL COMPOUNDS | NXERA PHARMA UK LIMITED (GB) | 2021-01-07 | — | — | US | disclosed |
| US-10787447-B2 | Pharmaceutical compounds | HEPTARES THERAPEUTICS LIMITED (GB) | 2020-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11773090-B2 | Pharmaceutical compounds | CHRM1, CHRM2, CHRM4 | MAPK1 1738/4885CHRM1 1/4885CHRM5 4/4885 |
| US-20210002271-A1 | PHARMACEUTICAL COMPOUNDS | CHRM1, CHRM2, CHRM4 | MAPK1 1738/4885CHRM1 1/4885CHRM5 4/4885 |
| US-10787447-B2 | Pharmaceutical compounds | CHRM1, CHRM2, CHRM4 | MAPK1 1738/4885CHRM1 1/4885CHRM5 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.